Your browser is no longer supported. Please, upgrade your browser.
MESO Mesoblast Limited daily Stock Chart
Mesoblast Limited
Index- P/E- EPS (ttm)-0.74 Insider Own- Shs Outstand101.95M Perf Week19.67%
Market Cap446.54M Forward P/E- EPS next Y-0.36 Insider Trans- Shs Float81.64M Perf Month-43.48%
Income-75.80M PEG- EPS next Q-0.17 Inst Own2.10% Short Float0.19% Perf Quarter-40.00%
Sales22.50M P/S19.85 EPS this Y-139.70% Inst Trans-17.27% Short Ratio1.07 Perf Half Y-35.78%
Book/sh4.69 P/B0.93 EPS next Y44.60% ROA-11.30% Target Price14.00 Perf Year-14.79%
Cash/sh0.80 P/C5.50 EPS next 5Y24.00% ROE-15.50% 52W Range3.12 - 10.88 Perf YTD-40.57%
Dividend- P/FCF- EPS past 5Y4.90% ROI-13.80% 52W High-57.68% Beta2.07
Dividend %- Quick Ratio1.20 Sales past 5Y-6.50% Gross Margin40.00% 52W Low47.56% ATR0.67
Employees83 Current Ratio1.20 Sales Q/Q15.80% Oper. Margin- RSI (14)40.32 Volatility9.38% 12.05%
OptionableYes Debt/Eq0.19 EPS Q/Q8.10% Profit Margin- Rel Volume1.81 Prev Close4.38
ShortableYes LT Debt/Eq0.15 EarningsFeb 26 Payout- Avg Volume148.70K Price4.60
Recom2.00 SMA20-7.12% SMA50-39.23% SMA200-28.21% Volume208,204 Change5.11%
Jan-31-19Resumed H.C. Wainwright Buy $6.50
Mar-22-18Downgrade Credit Suisse Neutral → Underperform
Feb-28-18Reiterated Cantor Fitzgerald Buy $20 → $23
Aug-31-17Initiated Oppenheimer Outperform $16
Jun-08-17Initiated Cantor Fitzgerald Buy
Mar-11-20 11:06AM  Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More Zacks -19.13%
Mar-10-20 06:00AM  Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L For Treatment Of COVID-19 Lung Disease GlobeNewswire +21.14%
Feb-28-20 07:35PM  Earnings Update: Mesoblast Limited Just Reported And Analysts Are Trimming Their Forecasts Simply Wall St. -11.25%
Feb-26-20 04:59PM  Mesoblast Reports Financial Results and Corporate Highlights for First Half Ended December 31, 2019 GlobeNewswire
Feb-25-20 06:00AM  Mesoblast to Host Analyst Call on First Half Financial Results for Period Ended December 31, 2019 GlobeNewswire
Feb-24-20 06:00AM  Consistent Outcomes Using Ryoncil as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD GlobeNewswire -8.55%
Feb-20-20 06:00AM  Clinically Meaningful Outcomes Using Remestemcel-L In Patients With Chronic Graft Versus Host Disease GlobeNewswire
Feb-03-20 06:00AM  Mesoblast Submits Completed Biologics License Application for Ryoncil to US FDA GlobeNewswire
Jan-23-20 03:26PM  Is Mesoblast Limited's (ASX:MSB) CEO Being Overpaid? Simply Wall St. +5.81%
10:18AM  Will Mesoblast Continue to Surge Higher? Zacks
Jan-20-20 09:59AM featured highlights include: China Distance Education, Intellicheck, Snap and Mesoblast Zacks
Jan-17-20 09:22AM  4 Affordable Breakout Stocks for Stunning Returns Zacks +13.00%
Jan-15-20 06:00AM  Mesoblast Presents Commercial Plans at 2020 Biotech Showcase in San Francisco GlobeNewswire
Jan-09-20 08:46AM featured highlights include: CNX Midstream Partners LP, Akoustis Technologies, CRH Medical, Mesoblast and Photronics Zacks
Jan-08-20 07:24AM  5 Breakout Stocks for Explosive Returns Zacks
Jan-03-20 07:19AM  Will Mesoblast Continue to Surge Higher? Zacks -6.13%
Jan-02-20 06:00AM  Mesoblast Submits Clinical Efficacy And Safety Data To FDA In Rolling Biologics License Application For Remestemcel-L GlobeNewswire +6.24%
Jan-01-20 05:45PM  Mesoblast Submits Clinical Efficacy and Safety Data to FDA in Rolling Biologics License Application for Remestemcel-l Benzinga
Dec-18-19 06:00AM  Data Monitoring Committee Completes Final Scheduled Review of Mesoblasts Phase 3 Trial of Revascor in Advanced Chronic Heart Failure GlobeNewswire -9.03%
Dec-17-19 06:00AM  Mesoblasts Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Surpasses the Number of Primary Endpoint Events for Trial Completion GlobeNewswire +9.12%
Dec-09-19 03:24PM  Trade Alert: The Independent Non-Executive Vice Chairman Of Mesoblast Limited (ASX:MSB), William A. Burns, Has Just Spent US$60k Buying Shares Simply Wall St.
Nov-29-19 03:26PM  AU$5.73 - That's What Analysts Think Mesoblast Limited Is Worth After These Results Simply Wall St.
Nov-25-19 04:52PM  Mesoblast Finanical Results for the Quarter Ended September 30, 2019 GlobeNewswire
Nov-21-19 04:29PM  Mesoblast to Host Analyst Call on Financial Results for First Quarter Ended September 30, 2019 GlobeNewswire
Oct-16-19 06:17PM  Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblasts Potential First United States Allogeneic Cell Therapy GlobeNewswire
Oct-08-19 08:10AM  Top Ranked Momentum Stocks to Buy for October 8th Zacks
Oct-03-19 07:59AM  Mesoblast Completes Successful Institutional Capital Raising of A$75 Million GlobeNewswire -7.36%
Sep-25-19 09:13AM  Will Mesoblast Continue to Surge Higher? Zacks
Sep-23-19 06:00AM  The Opioid Crisis Has Upended Pain Management. Whats Next for the Industry.
Sep-09-19 07:40PM  Mesoblast Corporate Update: Analyst Call GlobeNewswire
07:38PM  Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain GlobeNewswire
Aug-29-19 05:50PM  Mesoblast Reports 2019 Full Year Results GlobeNewswire
Aug-27-19 06:36PM  Mesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019 GlobeNewswire
06:00AM  FDA Provides Guidance on Clinical Pathway to Marketing Application for Revascor in End-Stage Heart Failure Patients With an LVAD GlobeNewswire
Aug-14-19 06:00AM  Remestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated Trial GlobeNewswire
Aug-12-19 06:00AM  Mesoblast Appoints Leading Pharmaceutical Industry Executive as Chief Medical Officer GlobeNewswire
Jul-31-19 06:00AM  Mesoblast Quarterly Cash Flow Report GlobeNewswire
Jul-27-19 08:50PM  Does The Mesoblast Limited (ASX:MSB) Share Price Tend To Follow The Market? Simply Wall St.
Jul-25-19 06:00AM  Circulation Research Special Article Highlights Potential Of Mesoblast Cell Therapy In Treatment Of Advanced Heart Failure GlobeNewswire
Jun-28-19 12:40AM  If You Had Bought Mesoblast (ASX:MSB) Stock Five Years Ago, You'd Be Sitting On A 69% Loss, Today Simply Wall St. +5.15%
Jun-25-19 04:32PM  Why Teva Pharmaceutical Industries, Mesoblast, and New Gold Jumped Today Motley Fool +12.00%
Jun-24-19 02:16PM  Mesoblast Trades Higher After Heart Failure Cell Therapy Receives Orphan Drug Status Benzinga +6.84%
06:00AM  Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices GlobeNewswire
Jun-18-19 06:00AM  High Economic Burden in Children With Steroid Refractory Acute Graft Versus Host Disease GlobeNewswire
Jun-14-19 10:28AM  Mesoblast to Host Virtual Symposium With Key Opinion Leader Highlighting Acute Graft Versus Host Disease GlobeNewswire
Jun-11-19 06:00AM  Mesoblast and JCR Pharmaceuticals Expand Japan License Agreement to Use of Mesenchymal Stem Cells in Newborns With Insufficient Blood Flow to the Brain GlobeNewswire
May-30-19 07:09PM  Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019 GlobeNewswire
04:51PM  Mesoblast Starts Rolling BLA Submission for Remestemcel-L Zacks
06:00AM  Mesoblast Financial Results Webcast for Period Ended March 31, 2019 GlobeNewswire
May-29-19 08:49PM  Mesoblast Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for remestemcel-L in the Treatment of Acute Graft Versus Host Disease GlobeNewswire
May-23-19 06:00AM  Mesoblast Keynote Presentations to Feature at 2019 Annual Meeting of the International Society for Cell and Gene Therapy GlobeNewswire
May-17-19 06:00AM  Mesoblast to Present at 2019 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-15-19 08:55PM  What Kind Of Shareholders Own Mesoblast Limited (ASX:MSB)? Simply Wall St.
Apr-16-19 06:00AM  FDA Agrees to Rolling Review of Mesoblasts Biologics License Application for Its Cell Therapy in Children With Steroid-Refractory Acute Graft Versus Host Disease GlobeNewswire
Apr-09-19 04:26PM  Should You Be Pleased About The CEO Pay At Mesoblast Limited's (ASX:MSB) Simply Wall St.
Apr-05-19 06:00AM  Mesoblast to Present at Upcoming Global Life Sciences Conference in London GlobeNewswire
Mar-26-19 11:00AM  Memorandum of Understanding for Confirmatory Trial to Support Marketing Approval of Revascor for Reduction of Gastrointestinal Bleeding in LVAD Patients GlobeNewswire +5.98%
Mar-25-19 06:00AM  Mesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa GlobeNewswire
Mar-22-19 04:36PM  U.S. Healthcare Leader Joseph R. Swedish Appointed Mesoblast Chairman GlobeNewswire
Mar-13-19 06:00AM  Mesoblast Features at Upcoming U.S. Investor Conferences GlobeNewswire
Feb-20-19 05:16PM  Mesoblast Reports Financial Results and Operational Highlights for the First Half Ended December 31, 2018 GlobeNewswire
Feb-19-19 06:00AM  Final Patient Dosed in Mesoblast Phase 3 Trial of Revascor Cell Therapy for Advanced Heart Failure GlobeNewswire
Feb-13-19 05:06PM  Mesoblast Financial Results Webcast for Half Year, Q2 Ended December 31, 2018 GlobeNewswire
Feb-04-19 08:10AM  New Research Coverage Highlights Symantec, YY, Workiva, Exponent, Ferroglobe, and Mesoblast Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Jan-14-19 10:46AM  Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs GlobeNewswire
Jan-13-19 04:56PM  Does The Mesoblast Limited (ASX:MSB) Share Price Tend To Follow The Market? Simply Wall St.
Jan-07-19 07:44PM  Mesoblast Highlights 2019 Key Priorities for its Leading Cellular Medicines Pipeline at Biotech Showcase in San Francisco GlobeNewswire
06:00AM  Phase 3 Trial of Mesoblasts Cell Therapy in Chronic Heart Failure Completes Recruitment GlobeNewswire
Dec-28-18 06:00AM  Mesoblast Corporate Review GlobeNewswire +9.72%
Dec-24-18 06:30AM  Mesoblast to Present at 2019 Biotech Showcase in San Francisco GlobeNewswire
Dec-19-18 07:22AM  Mesoblast Makes Executive Appointment to Drive Product Commercialization GlobeNewswire
Dec-13-18 06:00AM  Meetings Held With FDA Support Mesoblasts Planned Regulatory Filing for Commercialization of Remestemcel-L in Acute GVHD GlobeNewswire
Nov-29-18 07:35AM  Recent Analysis Shows HudBay Minerals, Meridian Bioscience, ArQule, Mesoblast, Concho Resources, and Liberty Global Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-26-18 06:00AM  Tasly and Mesoblast Initiate Development and Regulatory Activities for MPC-150-IM Heart Failure Cell Therapy in China GlobeNewswire
Nov-15-18 04:33PM  Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights GlobeNewswire
06:00AM  Mesoblast Financial Results Webcast for Quarter Ended September 30, 2018 GlobeNewswire
Nov-11-18 07:59PM  Clinically Meaningful Outcome in NIH Trial of MPC-150-IM for Heart Failure LVAD Recipients Provides Pathway for Potential Regulatory Approval GlobeNewswire
Nov-09-18 06:00AM  Mesoblast to Host Analyst Call on Results of End-Stage Heart Failure Trial Being Presented at 2018 American Heart Association Scientific Sessions GlobeNewswire
Oct-24-18 06:05AM  Mesoblast Expands Partnership With JCR Pharmaceuticals for Treatment of Wound Healing in Epidermolysis Bullosa GlobeNewswire -5.13%
Oct-22-18 08:25AM  Investor Expectations to Drive Momentum within ChannelAdvisor, WideOpenWest, Arcos Dorados, Mesoblast, Ferrari N.V, and Weatherford International Discovering Underlying Factors of Influence GlobeNewswire
Oct-12-18 06:00AM  Mesoblast and Tasly Pharmaceutical Group Complete Transaction for Strategic Cardiovascular Partnership in China GlobeNewswire
Oct-09-18 12:00PM  Orchestra BioMed Adds Three Industry Leaders to Strategic Advisory Board GlobeNewswire
Oct-02-18 06:00AM  Trial Results of Mesoblast Cell Therapy in End-Stage Heart Failure Selected as Late-Breaking Presentation at 2018 American Heart Association Scientific Sessions GlobeNewswire -17.79%
Sep-28-18 10:06AM  3 Biotech Stocks With Rising Estimates in the Past Month Zacks +7.23%
Sep-20-18 06:30AM  Children Treated With Remestemcel-L Continue to Have Strong Survival Outcomes at Six Months in Mesoblasts Phase 3 Trial for Acute Graft Versus Host Disease GlobeNewswire
Sep-17-18 06:00AM  Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast GlobeNewswire
Aug-30-18 04:50PM  Mesoblast Limited (ASX:MSB) Is Expected To Breakeven Simply Wall St.
Aug-29-18 06:56PM  Mesoblast Reports Fourth Quarter and Full-Year 2018 Financial Results and Operational Highlights GlobeNewswire
07:43AM  Mesoblast's Earnings Outlook Benzinga
Aug-28-18 09:04PM  Mesoblast Provides Update on Transaction With Tasly Pharmaceutical Group GlobeNewswire
Aug-21-18 07:30AM  Analysis: Positioning to Benefit within Alamos Gold, Nomad Foods, MyoKardia, Mesoblast, Core-Mark Holding, and Jounce Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jul-17-18 06:32AM  Mesoblast Enters Into Strategic Cardiovascular Alliance for China With Tasly Pharmaceutical Group GlobeNewswire +12.50%
06:17AM  BRIEF-Tasly Pharmaceutical To Invest $20 Million In Australia's Mesoblast Limited Reuters
Jul-11-18 06:00AM  Leading Commercial and Transactional Healthcare Executive Shawn Cline Tomasello Joins Mesoblast Board GlobeNewswire
Jul-02-18 06:00AM  Mesoblast Enters Into US$50M Financing with Novaquest Capital for Commercial Readiness of Remestemcel-l in the Treatment of Acute Graft Versus Host Disease GlobeNewswire +10.00%
Jun-21-18 09:28AM  Mesoblast Soars on Stem-Cell Treatment Data +9.39%
06:00AM  Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Disease Presented at 2018 ISSCR Annual Meeting GlobeNewswire
Jun-19-18 06:00AM  U.S. Healthcare Leader Joseph R. Swedish Joins Mesoblast Board GlobeNewswire
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grunenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.